Nrc Health (NRC) · Oct 27, 2026 · Earnings
In line — Revenue $38.4M, adjusted EPS $0.21; no reliable published consensus located
NRC Health’s third-quarter earnings show 11% revenue growth and rising recurring contracts, but weaker year-to-date margins temper the recovery.
NRC Health is rebuilding after earlier sales, retention, product-innovation, and management-transition problems; the current strategy is to turn a growing subscription contract base with large healthcare systems into sustained revenue and operating leverage. Its TRCV had already climbed to record levels by early 2026, so stronger revenue was expected directionally rather than coming out of nowhere.
Revenue conversion is working. Third-quarter revenue rose 11% year over year to $38.4 million, while TRCV increased 9% to $154.1 million, supporting the thesis that the contracted-revenue recovery is beginning to flow through the income statement. 〔0〕
| Metric | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Revenue | $38.4M | $34.6M | $108.6M | $102.2M |
| GAAP diluted EPS | $0.21 | $0.18 | $0.20 | $0.43 |
| Adjusted diluted EPS | $0.21 | $0.23 | $0.73 | $0.77 |
| Adjusted EBITDA | $10.9M | $10.9M | $29.7M | $31.5M |
| Adjusted EBITDA margin | 28% | 31% | 27% | 31% |
| Free cash flow | $7.0M | $10.2M | $12.4M | $9.7M |
The quarter improved, but the broader earnings recovery is incomplete. GAAP EPS increased year over year, yet adjusted EPS fell from $0.23 to $0.21 and adjusted EBITDA margin contracted from 31% to 28% in the quarter. For the first nine months, adjusted EBITDA declined 6% and the margin fell four percentage points, showing that revenue growth has not yet translated into sustained operating leverage. (Adjusted EBITDA reconciliation) 〔1〕
Cash generation is better year to date, but balance-sheet flexibility is limited. Nine-month free cash flow rose to $12.4 million from $9.7 million because capital spending fell sharply, but operating cash flow declined to $16.6 million from $19.3 million. The company also ended September with only $3.6 million of cash against roughly $102.9 million of notes payable, while shareholders’ equity was negative $9.1 million. (Cash Flow statement; Balance Sheet)
The customer story is validating, but not yet fully monetized. The company says a large customer went live on schedule and several long-standing customers renewed under multi-year agreements, which supports retention and future revenue visibility. 〔2〕 That direction was already known from prior updates, making this quarter more confirmation than a new demand shock.
Bottom line: NRC Health is successfully converting a stronger recurring-contract base into double-digit revenue growth, but profitability remains behind the recovery narrative. The filing matters as confirmation of progress, not as proof that operating leverage has fully arrived.
Q4 results, early February 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!